Insights

Gathering insights about Fairchild…

Similar companies to Fairchild

Fairchild Tech Stack

Fairchild uses 8 technology products and services including MSCI, Nintex, Cadence OrCAD, and more. Explore Fairchild's tech stack below.

MSCI
Accounting And Finance
Nintex
Business Process Management
Cadence OrCAD
Cad & Graphics
CCPA
Certificates
Microsoft SQL Server
Database
MLflow
Development
Apache Subversion
Source Code Management
Flask
Web Frameworks

Media & News

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potent.
Jan 07, 2026 | www.businesswire.com
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLO™ (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate. FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 ti.
Jan 05, 2026 | www.businesswire.com
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 people in the U.S. living with genetic or clinical FCS, characterized by triglyceride levels that can be 10 to 100 ti.
Nov 18, 2025 | www.businesswire.com
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The approval follows the positive opinion of the Committee for Medicinal Products for Human Use. The approval is based on positive data from the Phase 3 Balance study, in which TRYNGOLZA 80 mg demon.
Sep 19, 2025 | www.businesswire.com
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The positive opinion is now referred to the European Commission (EC) for an approval decision, which is expected by Q4.
Jul 25, 2025 | www.businesswire.com
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We'll Get There Soon campaign, initially launched for healthcare providers in November 2024. This new phase introduces a dedicated educational website, www.LowerMyTGs.com, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS). FCS is an ultra-rare genetic disorder that signi.
Feb 28, 2025 | www.businesswire.com
Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
Ionis Pharmaceuticals applies proprietary antisense technology to tackle diseases at their genetic source, focusing on conditions such as FCS, Angelman syndrome, and HAE. The FDA approval of Tryngolza for FCS positions Ionis as the first company to independently develop and launch an RNA-targeted therapy. Ionis forecasts that its pipeline, containing approximately 40 investigational drugs, could generate billions in peak sales, with four launches projected in the next three years.
Dec 23, 2024 | seekingalpha.com

Fairchild's Email Address Formats

Fairchild uses at least 2 format(s):

Fairchild Email Formats	Example	Percentage
First.Last@fairchildsemi.com	John.Doe@fairchildsemi.com	91%
FLast@fairchildsemi.com	JDoe@fairchildsemi.com	3%
FiLast@fairchildsemi.com	JoDoe@fairchildsemi.com	2%
Last.First@fairchildsemi.com	Doe.John@fairchildsemi.com	1%
FirLast@fairchildsemi.com	JohDoe@fairchildsemi.com	1%
First.Middle.Last@fairchildsemi.com	John.Michael.Doe@fairchildsemi.com	1%
LastFi@fairchildsemi.com	DoeJo@fairchildsemi.com	1%
First.Last@onsemi.com	John.Doe@onsemi.com	94%
First.L@onsemi.com	John.D@onsemi.com	3%
Last@onsemi.com	Doe@onsemi.com	2%
FirstLast@onsemi.com	JohnDoe@onsemi.com	1%

Frequently Asked Questions

Where is Fairchild's headquarters located?

Fairchild's main headquarters is located at 5005 East Mcdowell Road Phoenix, Arizona 85008 United States. The company has employees across 6 continents, including North AmericaAsiaEurope.

What is Fairchild's phone number?

You can contact Fairchild's main corporate office by phone at

+1-703-478-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Fairchild's stock symbol?

Fairchild is a publicly traded company; the company's stock symbol is FCS.

What is Fairchild's official website and social media links?

Fairchild's official website is onsemi.com and has social profiles on LinkedIn.

How much revenue does Fairchild generate?

As of March 2026, Fairchild's annual revenue is estimated to be $7.1B.

What is Fairchild's SIC code NAICS code?

Fairchild's SIC code is 3674 - Semiconductors and Related Devices NAICS code is 3344 - Semiconductor and Other Electronic Component Manufacturing.

How many employees does Fairchild have currently?

As of March 2026, Fairchild has approximately 2.6K employees across 6 continents, including North AmericaAsiaEurope. Key team members include Chief Executive Officer: A. W.Chief Executive Officer: C. B.Chief Executive Officer: D. C.. Explore Fairchild's employee directory with LeadIQ.

What industry does Fairchild belong to?

Fairchild operates in the Semiconductor Manufacturing industry.

What technology does Fairchild use?

Fairchild's tech stack includes MSCINintexCadence OrCADCCPAMicrosoft SQL ServerMLflowApache SubversionFlask.

What is Fairchild's email format?

Fairchild's email format typically follows the pattern of First.Last@fairchildsemi.com. Find more Fairchild email formats with LeadIQ.

Fairchild

Q: What is Fairchild's official website and social media links?

Fairchild's official website is onsemi.com. Fairchild has social profiles on LinkedIn.

Q: How many employees does Fairchild have currently?

Fairchild has approximately 2.6K employees.

Q: What technology does Fairchild use?

Fairchild's tech stack includes LinkedIn, Synopsys PrimeTime, Oracle Procurement, Microsoft Word, Akamai Bot Manager.

Semiconductor ManufacturingArizona, United States1001-5000 Employees

Fairchild -- now part of ON Semiconductor -- has a rich history as a pioneer in the semiconductor industry and that pioneering spirit endures today. In an era where diversity can dilute focus and hamper innovation, we specialize in the development and manufacturing of a complete portfolio of low- to high-power solutions for the mobile, industrial, cloud, automotive, lighting, and computing industries. 

Connect with us over on the at ON Semiconductor page to see how we are driving energy efficient innovations and empowering customers to reduce global energy use. http://bit.ly/2nt0wcG

Company Overview

Headquarters: 5005 East Mcdowell Road Phoenix, Arizona 85008 United States
Phone number: +1-703-478-****
Website: onsemi.com
SIC Code: 3674 - Semiconductors and Related Devices
Stock Symbol: FCS
NAICS Code: 3344 - Semiconductor and Other Electronic Component Manufacturing
Employees: 1001-5000

Media & News

Funding & Financials

$1B$10B
Fairchild's revenue is estimated to be in the range of $1B$10B

Funding & Financials

$1B$10B
Fairchild's revenue is estimated to be in the range of $1B$10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Fairchild

STMicroelectronics

Toshiba

Infineon Technologies

NXP Semiconductors

Texas Instruments

Fairchild Tech Stack

Media & News

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Fairchild's Email Address Formats

Frequently Asked Questions

Where is Fairchild's headquarters located?

What is Fairchild's phone number?

What is Fairchild's stock symbol?

What is Fairchild's official website and social media links?

How much revenue does Fairchild generate?

What is Fairchild's SIC code NAICS code?

How many employees does Fairchild have currently?

What industry does Fairchild belong to?

What technology does Fairchild use?

What is Fairchild's email format?

Fairchild

Company Overview

Media & News

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?